This case series examines numbers of US clinicians receiving waivers from the Drug Enforcement Administration allowing them to prescribe buprenorphine for opioid use disorder before and during the COVID-19 pandemic.
No takes yet. Share an insight, caveat, or question.
Spetz et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: